Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle ...
– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo –
Source: eagletribune.com
Multicenter Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Multicenter Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Multicenter Study Today - Breaking & Trending Today
Mitapivat Shows Promise for Sickle Cell Disease in Phase 2 RISE UP Trial
Results of the phase 2 RISE UP trial offer additional perspective into the benefit-risk profile of mitapivat in patients with sickle cell disease.
Source: hcplive.com
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain...
Source: marketscreener.com
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral ...
The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in
Source: eagletribune.com
87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ('Abbisko Therapeutics' hereafter) announced that two major clinical updates...
Source: businessinsider.com